Perseus Proteomics Inc
TSE:4882

Watchlist Manager
Perseus Proteomics Inc Logo
Perseus Proteomics Inc
TSE:4882
Watchlist
Price: 570 JPY -3.72% Market Closed
Market Cap: 8.4B JPY
Have any thoughts about
Perseus Proteomics Inc?
Write Note

Perseus Proteomics Inc
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Perseus Proteomics Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Perseus Proteomics Inc
TSE:4882
Net Change in Cash
-ÂĄ903.5m
CAGR 3-Years
N/A
CAGR 5-Years
-21%
CAGR 10-Years
N/A
GNI Group Ltd
TSE:2160
Net Change in Cash
-ÂĄ4.1B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
PeptiDream Inc
TSE:4587
Net Change in Cash
ÂĄ36.8B
CAGR 3-Years
103%
CAGR 5-Years
69%
CAGR 10-Years
N/A
Takara Bio Inc
TSE:4974
Net Change in Cash
ÂĄ2.2B
CAGR 3-Years
-23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Pharma Foods International Co Ltd
TSE:2929
Net Change in Cash
-ÂĄ739m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
C
Cuorips Inc
TSE:4894
Net Change in Cash
ÂĄ2.6B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Perseus Proteomics Inc
Glance View

Market Cap
8.4B JPY
Industry
Biotechnology

Perseus Proteomics, Inc. is a holding company that develops antibody-based therapeutics and diagnostics. The company is headquartered in Meguro-Ku, Tokyo-To and currently employs 21 full-time employees. The company went IPO on 2021-06-22. The firm is involved in the research and development of therapeutic drugs for cancer and other diseases and related businesses. The firm is involved in the research, development, licensing, and manufacturing method establishment for commercialization in the fields of drug discovery, antibody research support, as well as antibody and reagent sales. The products include PPMX-T001, a therapeutic agent that targets glypican 3 (GPC3) present on the surface of cancer cell membranes; PPMX-T002, a therapeutic agent that targets cadherin 3 (CDH3) present on the surface of cancer cells; PPMX-T003, a therapeutic agent that targets the transferrin receptor (TfR); PPMX-T004 therapeutic agent targeting cadherin 3 (CDH3) and others.

Intrinsic Value
732.02 JPY
Undervaluation 22%
Intrinsic Value
Price

See Also

What is Perseus Proteomics Inc's Net Change in Cash?
Net Change in Cash
-903.5m JPY

Based on the financial report for Mar 31, 2024, Perseus Proteomics Inc's Net Change in Cash amounts to -903.5m JPY.

What is Perseus Proteomics Inc's Net Change in Cash growth rate?
Net Change in Cash CAGR 5Y
-21%

Over the last year, the Net Change in Cash growth was -17%.

Back to Top